Abstract:
The COVID-19 pandemic represents one of the world's most important_challeng es for global public healthcare. Attttough there have been advances in preventing and treating
COVIDI1g thrbugh the utilization of effective vaccines and antiviral drugs, interest in the nutra ceutical "ppro"& , particularly in vitamin D , as a means to promote the immune response and
reduce thllnflammatory response has been growing. Howeveq, vitamin D deficiency is associat ed with not only immun-e response also it is consistently associated with cardiovascular disease,
wtrich may be o-ne of the risk factors for the development of severe complications of Covid-19. For
instance, iow*, baseline vitamin D levels have been comelated with atherogenic blood lipid pro-_
files, Z S iOffl O supplementation influences the levels of serum lipids_ in ttrat it lowers the levels of
total cholesierol, triglycerides, and LDl-cholesterol and increases the levels of HDl-cholesterol,
all of which are }rrofrn risk factors for cardiovascular disease. In our country, information on the
prevalence of vitamin D deficiency is very limited, especially a prospective study of vitamin D me bbofsm in post-COVID-lg patients has not yet been studied.
